HC Wainwright Reiterates “Buy” Rating for Tango Therapeutics (NASDAQ:TNGX)

Tango Therapeutics (NASDAQ:TNGX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $13.00 price target on the stock. HC Wainwright also issued estimates for Tango Therapeutics’ Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.

Tango Therapeutics Stock Up 2.6 %

NASDAQ TNGX opened at $1.38 on Monday. The firm has a 50-day moving average price of $1.88 and a two-hundred day moving average price of $3.39. Tango Therapeutics has a 12-month low of $1.11 and a 12-month high of $12.02. The company has a market capitalization of $148.65 million, a P/E ratio of -1.17 and a beta of 1.03.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. Equities analysts expect that Tango Therapeutics will post -1.19 EPS for the current year.

Insider Transactions at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the sale, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders have sold 24,268 shares of company stock valued at $72,561. 6.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas boosted its position in shares of Tango Therapeutics by 35.8% during the 4th quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock worth $45,000 after acquiring an additional 3,831 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Tango Therapeutics by 29.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company’s stock valued at $65,000 after purchasing an additional 4,813 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Tango Therapeutics by 24.1% in the 4th quarter. Deutsche Bank AG now owns 36,653 shares of the company’s stock valued at $113,000 after purchasing an additional 7,128 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Tango Therapeutics by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 22,292 shares of the company’s stock worth $69,000 after buying an additional 7,599 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Tango Therapeutics during the 4th quarter worth $33,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.